옵션 체인은 다양한 행사가격과 만기일에 대한 NOVONIX의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 NOVONIX에 대한 시장 심리를 평가합니다..

NOVONIX (OTC:NVNXF) 주식, 옵션 체인

NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration and Mining, Battery Technology, and NOVONIX Anode Materials. Graphite Exploration and Mining segment is engaged in the exploration and development of high-grade flake graphite deposits. The NOVONIX Anode Materials segment develops and manufactures battery anode materials. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Technology segment generates maximum revenue for the company.

NOVONIX Ltd

Stephens &amp; Co. analyst Jim Salera reiterates Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Equal-Weight and maintains $164 price target.

News

Price Target

Reiteration

Analyst Ratings

Stephens & Co. Reiterates Equal-Weight on Darden Restaurants, Maintains $164 Price Target

Northcoast Research analyst Aaron Reed initiates coverage on Tennant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNC#NYSE">TNC</a>) with a Buy rating and announces Price Target of $125.

Initiation

Northcoast Research Initiates Coverage On Tennant with Buy Rating, Announces Price Target of $125

Rodman &amp; Renshaw analyst Tony Butler initiates coverage on TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) with a Buy rating and announces Price Target of $11.

HURA

Rodman & Renshaw Initiates Coverage On TuHURA Biosciences with Buy Rating, Announces Price Target of $11

WIIM

PHIO

Phio Pharmaceuticals shares are trading higher after the company announced that the Safety Monitoring Committee recommended dose escalation in its Phase 1B trial evaluating PH-762 for various advanced cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

Baird analyst Tristan Gerra maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and lowers the price target from $150 to $130.

Baird Maintains Outperform on Micron Technology, Lowers Price Target to $130

Keybanc analyst Eric Heath downgrades C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) from Sector Weight to Underweight and announces $29 price target.

Downgrades

Keybanc Downgrades C3.ai to Underweight, Announces $29 Price Target

Vladimir Putin, the President of Russia, has <a href="https://www.benzinga.com/news/global/24/11/41865062/putin-congratulates-trump-on-2024-election-victory-russian-leader-said-president-elect-manly-for-how-he-handled-assassination-attempt">shown his readiness to initiate talks</a> with the incoming U.S. President Donald Trump. 
What Happened: In his annual televised press conference held in Moscow, Putin stated his readiness to engage in dialogue with Trump,  <a href="https://www.bloomberg.com/news/articles/2024-12-19/putin-says-he-s-ready-to-meet-trump-hasn-t-seen-syria-s-assad">Bloomberg</a> on Thursday.
&#8220;I&#8217;m ready for it, of course, at any time. And I&#8217;ll be ready to meet if he wants,&#8221; he said. Trump, who is due to begin his second term as US president on Jan.20, has expressed his intent to resolve the ongoing war between Russia and Ukraine, which has been ongoing for nearly three years.
Trump Campaign did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/24/12/42522048/jim-cramer-warns-nvidias-vicious-and-fast-reversal-is-coming-amid-174-surge-this-year-and-china-antitrust-probe?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Warns Nvidia&#8217;s &#8216;Vicious&#8217; And &#8216;Fast&#8217; Reversal Is Coming Amid 174% Surge This Year And China Ant</a>
Trump has also hinted at his expectation for Putin to be open to a deal. However, the details of how he intends to bring both parties to the negotiation table and the terms of the potential agreement remain undisclosed.
Why It Matters: Putin also disclosed that he has not had any interaction with the deposed Syrian President Bashar al-Assad, who sought refuge in Moscow earlier this month. &#8220;I haven&#8217;t seen President Assad since his arrival in Moscow,&#8221; Putin stated. He also mentioned his plans to meet with Assad to discuss various matters, including the case of Austin Tice, the American journalist who has been missing. Earlier, Trump <a href="https://www.benzinga.com/news/global/24/12/42380085/trump-on-assads-fall-putin-was-not-interested-in-protecting-him-any-longer">commented on Putin&#8217;s lack of interest</a> in protecting Assad following the dictator&#8217;s fall.
Meanwhile, a book by journalist Bob Woodward in October<a href="https://www.benzinga.com/general/politics/24/10/41235596/trump-secretly-stayed-in-contact-with-putin-after-leaving-office-upcoming-bob-woodward-book-alle"> reportedly alleged that Trump and Russian President </a>Putin have spoken as many as seven times since 2021.
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42516580/ionq-quantum-computing-and-rigetti-computing-shares-are-soaring-monday-whats-going-on?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">IonQ, Quantum Computing And Rigetti Computing Shares Are Soaring Monday: What&#8217;s Going On?</a>
Image via Kremlin

Politics

General

Russian President Says He's Willing To Meet Trump 'At Any Time' For Dialogue

Baird analyst Mark Altschwager maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and raises the price target from $65 to $72.

BIRK

Baird Maintains Outperform on Birkenstock Holding, Raises Price Target to $72

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Biotech

Health Care

Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial To Evaluate The Safety And Tolerability Of PH-762 For Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And Stage 4 Merkel Cell Carcinoma

"We are encouraged by the early evidence of responses in patients with cold tumors, including MSS colorectal cancer, reported for the combination of vilastobart and atezolizumab in Phase 1C dose escalation earlier this year, and we look forward to sharing initial Phase 2 data for the combination in MSS CRC at ASCO GI in January," said Katarina Luptakova, M.D., chief medical officer of Xilio.
"In addition, the preliminary Phase 1 data we reported today for XTX301, our tumor-activated IL-12, highlight its promising clinical profile, including no dose-limiting toxicities reported to date and consistent interferon gamma signaling observed throughout treatment cycles."

Xilio To Present Initial Data From Its Ongoing Phase 2 Trial For Vilastobart At ASCO GI; Reports Preliminary Phase 1 Data For XTX301 Showing Improved Tolerability Profile Over Historical Data For rhIL-12

Deutsche Bank analyst David Begleiter maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Buy and lowers the price target from $150 to $145.

Deutsche Bank Maintains Buy on PPG Indus, Lowers Price Target to $145

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Paychex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>)</h3>
<ul>
<li>On Nov. 19, JP Morgan analyst Tien-Tsin Huang maintained Paychex with an Underweight rating and raised the price target from $133 to $139. The company's stock fell around 4% over the past five days and has a <a href="https://www.benzinga.com/quote/PAYX">52-week low of $114.72</a>.</li>
<li>RSI Value: 29.58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PAYX Price Action: Shares of Paychex fell 3.2% to close at $135.86 on Wednesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1">latest PAYX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164.png" alt="" class="wp-image-699579" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074317/image-164-768x719.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Sunrun Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Dec. 17, Goldman Sachs analyst Brian Lee maintained Sunrun with a Buy and lowered the price target from $19 to $17. The company's stock fell around 12% over the past five days and <a href="https://www.benzinga.com/quote/RUN">has a 52-week low</a> of $9.13.</li>
<li>RSI Value: 28.40</li>
<li>RUN Price Action: Shares of Sunrun fell 9.1% to close at $9.15 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"> trend in RUN stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165.png" alt="" class="wp-image-699581" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074410/image-165-768x706.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">A O Smith Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>)</h3>
<ul>
<li>On Dec. 11, Stifel analyst Nathan Jones maintained A.O. Smith with a Buy and lowered the price target from $91 to $90. The company's stock fell around 5% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/AOS">low of $68.89.</a></li>
<li>RSI Value: 25.09</li>
<li>AOS Price Action: Shares of A O Smith fell 2.7% to close at $68.91 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1">breakout in AOS shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="927" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166.png" alt="" class="wp-image-699582" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19074507/image-166-768x693.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42553288/top-3-tech-and-telecom-stocks-that-may-crash-this-month">Top 3 Tech And Telecom Stocks That May Crash This Month</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

PAYX

Top 3 Industrials Stocks Which Could Rescue Your Portfolio For December

Deutsche Bank analyst David Begleiter maintains Axalta Coating Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) with a Buy and lowers the price target from $44 to $42.

AXTA

Deutsche Bank Maintains Buy on Axalta Coating Sys, Lowers Price Target to $42

Wells Fargo analyst Derek Archila downgrades Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) from Overweight to Equal-Weight and lowers the price target from $12 to $6.

CABA

Wells Fargo Downgrades Cabaletta Bio to Equal-Weight, Lowers Price Target to $6

Keybanc analyst Eric Heath upgrades Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) from Sector Weight to Overweight and announces $115 price target.

Upgrades

FTNT

Keybanc Upgrades Fortinet to Overweight, Announces $115 Price Target

Deutsche Bank analyst Steve Powers maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Hold and lowers the price target from $72 to $68.

Deutsche Bank Maintains Hold on General Mills, Lowers Price Target to $68

Deutsche Bank analyst Krisztina Katai maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Buy and raises the price target from $65 to $66.

Deutsche Bank Maintains Buy on Birkenstock Holding, Raises Price Target to $66

Wells Fargo analyst Derek Archila upgrades C4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCC#NASDAQ">CCCC</a>) from Equal-Weight to Overweight and raises the price target from $8 to $12.

CCCC

Wells Fargo Upgrades C4 Therapeutics to Overweight, Raises Price Target to $12

NLSP

NLS Pharmaceutics And Kadimastem In Collaboration With iTolerance Announced That Request For Pre-Investigational New Drug Meeting Has Been Submitted To The FDA For iTOL102 For Type 1 Diabetes

Graphite Miners News For The Month Of November 2024

NOVONIX Ltd (AU:NVX) has released an update. Phillips 66 Company (P66) has reduced its voting power in Novonix Limited from 16.16% to 13.75% due to...

Phillips 66 Adjusts Stake in Novonix Limited

NOVONIX (NVX) and Gamry Instruments announced a strategic collaboration that will allow for the integration of a Gamry EIS box with a NOVONIX Ultra...

Novonix enters collaboration with Gamry Instruments

NOVONIX Ltd (AU:NVX) has released an update. Novonix Ltd recently held an Investor Day, highlighting its strategic initiatives and growth plans in ...

Novonix Outlines Growth Strategy Amid Rising Battery Demand

NOVONIX Ltd (AU:NVX) has released an update. NOVONIX Ltd has announced the cessation of 724,205 performance rights as the conditions for these secu...

NOVONIX Ltd Announces Cessation of Securities

NOVONIX Ltd (AU:NVX) has released an update. NOVONIX Limited has announced the issuance of 211,129 performance rights under an employee incentive s...

NOVONIX Issues Unquoted Performance Rights to Employees

Novonix (NVX) "announced a conditional commitment to NOVONIX through one if its wholly-owned U.S.-based subsidiaries, from the U.S. Department of E...

Novonix offered conditional commitment for $754M DoE loan for new facility

Graphite miners seek 920% tariff on Chinese imports of battery material

Novonix (NVX) announced the company's participation in the American Active Anode Material Producers', or AAAMP, petition to the U.S. Department of ...

Novonix announces participation in AAAMP petition

NOVONIX Ltd (AU:NVX) has released an update. NOVONIX Ltd has joined a coalition of American graphite producers in filing a trade case against China...

NOVONIX Joins Trade Case Against Chinese Graphite Practices

AMVMF

APMFF

BSSMF

CBULF

CYLYF

DMNKF

ECGFF

ECORF

EVMIF

FCSMF

FGPHF

GBMIF

GEMSF

GPHOF

GRFX

GRFXF

IMYSF

IMYSY

JRVMF

LEMIF

LMRMF

MGPHF

MNSEF

NGPHF

NNXPF

NSRCF

NVNXF

RFLXF

SGLFF

SRHYY

STSBF

SVMLF

SYAAF

TLGRF

TORVF

ZTEK

Press Releases

NOVONIX Announces Participation in the H.C. Wainwright Conference

NOVONIX to Host Third Quarter 2024 Operations Update and Participate in OTC Small Cap Growth Conference

Voltaiq and NOVONIX Announce Strategic Partnership to Drive Efficiency and Quality in the Battery Industry

NOVONIX and ICoNiChem Enter into Collaboration Agreement Focused on Sustainable Cathode Material Feedstock

NOVONIX and Stellantis Sign Binding Offtake Agreement

Contracts

NOVONIX and PowerCo SE Sign Binding Offtake Agreement

NOVONIX Announces December Investor Events

NOVONIX Announces Electrochemical Impedance Spectroscopy Partnership with Gamry Instruments Inc.

Financing

NOVONIX Offered Conditional Commitment for US$754 Million Loan from the U.S. Department of Energy for New Synthetic Graphite Manufacturing Plant in Tennessee

American Graphite Producers File Trade Case with U.S. Government Over Anticompetitive Graphite Prices on Chinese Exports

NOVONIX

Comments

NOVONIX

NOVONIX (NVNXF) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌